Back to News
Market Impact: 0.18
Inomagen Therapeutics, Inc. Awarded NIH SBIR Grant Providing up to $2.9 million to Advance Disease-Modifying Gene Therapy for Atrial Fibrillation
Source: PR Newswire
Healthcare & BiotechTechnology & Innovation
Inomagen Therapeutics received an award to fund key preclinical and manufacturing activities for its non-viral gene-therapy program. The funding is intended to advance the program toward a future Investigational New Drug application, representing a positive early-stage development milestone, though the award amount and program timeline were not disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Companies promised AI gains— here's how the payoff showed up in earnings
- Fears over $828 billion AI capex spending spree help erase $1 trillion in market value
- Intel stock plunges 29%. Analysts urge caution on buying the dip
- How Ambani’s Jio became India’s second-largest company
- From Karl Marx’s vampire to Warren Buffett’s moat, the crumbling gothic castle has been capitalism’s favorite metaphor for 250 years
- Anthropic's path to the Nasdaq just got a lot bumpier